

A comprehensive compilation of hard-to-find news/company announcements of the last 24 hours, stock price changes of the last trading session and the latest quarter's financial performance of companies in Japan's Life Science sector.

[Last 24 Hours' News](#) | [Today's Stock Movement](#) | [Gainers & Decliners](#) | [Latest Quarter Financial Performance](#)

SECTION A : NEWS

Companies Covered in News:

3 D Matrix Ltd | Acucela Inc. | Astellas Pharma Inc. | Ono Pharmaceutical Co., Ltd. | Taisho Pharmaceutical Holdings Co., Ltd. | Takeda Pharmaceutical Company Ltd

Company News - By Company Name

3 D Matrix Ltd ([www](http://www.3dmatrix.com)), (Ticker: 7777)

Absorbable Hemostat PuraStat® product registration obtained in Australia - The 3-D Matrix group is working towards commercialization of absorbable hemostat PuraStat® globally. The company announced that the subsidiary, 3-D Matrix Asia Pte. Lt. (3DMA), has received notification that the medical device product registration approval in Australia has been granted by the Australian regulatory body, Therapeutic Goods Administration (TGA). [More...](#) (January 22, 2016)

Acucela Inc. ([www](http://www.acucela.com)), (Ticker: 4589)

Kubota Ryo reduced position in Acucela Inc - Mr. Kubota Ryo has filled a SC 13D/A form regarding the company. As per Mr. Kubota Ryo's filing, the filler reported decreased stake in the company by -75.63 % to 10,250,654 shares. [More...](#) (January 22, 2016)

Astellas Pharma Inc. ([www](http://www.astellas.com)), (Ticker: 4503)

Repatha® (Evolocumab) approved as first PCSK9 inhibitor in Japan for the treatment of high cholesterol - Amgen Astellas BioPharma K.K. and the company announced that Amgen Astellas received approval for the cholesterol-lowering medication Repatha® (evolocumab) Injection, the first proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor in Japan from the Japanese Ministry of Health, Labour and Welfare. [More...](#) (January 22, 2016)

Astellas extends tender offer to acquire all outstanding shares of Ocata Therapeutics - Astellas is committed to transaction, acquisition of Ocata is a strategic priority - The company and Ocata Therapeutics, Inc. announced that Astellas has extended, through its indirect wholly-owned subsidiary Laurel Acquisition Inc., the offering period of the tender offer to purchase all issued and outstanding shares of common stock of Ocata for a price of USD8.50 per share, net to the holder in cash on February

9, 2016. [More...](#) (January 22, 2016)

Ono Pharmaceutical Co., Ltd. ([www](#)), (Ticker: 4528)

FDA approves new Kyprolis® (Carfilzomib) combination therapy for the treatment of patients with relapsed or refractory multiple myeloma - Amgen announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) of Kyprolis® (carfilzomib) for Injection in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy. [More...](#) (January 22, 2016)

Taisho Pharmaceutical Holdings Co., Ltd. ([www](#)), (Ticker: 4581)

Agent for Osteoporosis approved in Japan "Bonviva® Tablet" - Taisho Pharmaceutical Co., Ltd. announced that Chugai obtained approval of ibandronate sodium hydrate tablet [brand name: Bonviva® Tablet 100mg (Bonviva Tablet)], a bisphosphonate antiresorptive agent which was developed by F. Hoffmann-La Roche, Ltd. and, in Japan, by Taisho co-developed with Chugai, from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the osteoporosis indication. [More...](#) (January 22, 2016)

Takeda Pharmaceutical Company Ltd ([www](#)), (Ticker: 4502)

Broad Institute Genomic Services partners with Takeda Pharmaceuticals to offer genomic insight into the recently approved therapeutic NINLARO® (ixazomib) - Broad Institute Genomic Services has partnered with Takeda Pharmaceutical Company Limited to perform genomic analysis on patient samples from a Phase 3 clinical trial of NINLARO® (ixazomib), an oral proteasome inhibitor that was recently approved by the U.S. Food and Drug Administration (FDA), indicated in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy. [More...](#) (January 22, 2016)

Takeda announces new drug application approval in Japan for a Haemophilus influenzae type b conjugate vaccine, "VAXEM Hib®" - Takeda Pharmaceutical Company Limited announced that the Japanese Ministry of Health, Labour and Welfare has approved the New Drug Application ("NDA") for a conjugate vaccine to prevent infections caused by Haemophilus influenzae type b (Hib) in children aged from 2 months to under 5 years of age. [More...](#) (January 22, 2016)

European Commission approves label variation for ADCETRIS® (Brentuximab Vedotin) to include data on retreatment of adult patients with relapsed or refractory hodgkin lymphoma and systemic anaplastic large cell lymphoma - Takeda Pharmaceutical Company Limited announced that the European Commission (EC) has approved a Type II variation for ADCETRIS® (brentuximab vedotin) to include data on the retreatment of adult patients with relapsed or refractory (R/R) Hodgkin lymphoma or R/R systemic anaplastic large cell lymphoma (sALCL) who previously responded to ADCETRIS and who later relapse. The decision from the EC follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in October 2015. [More...](#) (January 22, 2016)

SECTION B : STOCK PRICE CHANGES

Stock Analysis - Top Gainers and Decliners in Japan Life Science Sector

Country	Company	Stock Price Jan 25, 2016	Stock Price Jan 22, 2016	Current Day % Chg
Top Gainers				
Japan	Techno Horizon Holdings Co Limited (6629)	277	210	31.9
Japan	Carna Biosciences, (4572)	2126	1726	23.17
Japan	Daiken Medical Company., Limited (7775)	923	803	14.94
Japan	tella, Inc. (2191)	669	590	13.39
Japan	CanBas Co.,Ltd. (4575)	672	598	12.37
Japan	ND Software Co Ltd (3794)	1067	951	12.2
Japan	Medical Data Vision Co Ltd (3902)	2062	1842	11.94
Japan	Shin Nippon Biomedical Laboratories (2395)	359	323	11.15
Japan	Yamane Medical Corp (2144)	200	180	11.11
Japan	SMS Co.,Ltd. (2175)	2288	2066	10.75
Top Decliners				
Japan	Tamron Co Ltd (7740)	1741	1870	-6.9
Japan	Nakanishi Incorporated (7716)	4430	4535	-2.32
Japan	Hoshi Iryo-Sanki Co., Ltd. (7634)	3150	3220	-2.17
Japan	Medical Biological Laboratories Co... (4557)	440	446	-1.35
Japan	Medikit Co Ltd (7749)	3480	3525	-1.28
Japan	Fukuda Denshi Co., Ltd. (6960)	5870	5900	-0.51
Japan	Kel Corporation (6919)	384	385	-0.26
Japan	Sogo Medical (4775)	3560	3565	-0.14

SECTION C : FINANCIAL PERFORMANCE OF JAPAN LIFE SCIENCE SECTOR

C-1 Fastest Growing

Company	Ticker	Sub-Industry	Overall Rank	Sales Growth Rank	Sales Growth %	Assets Growth Rank	Assets Growth %
Imageone Company Ltd.	2667	M-D/T/S	1	4	225.74	3	26.70
Tsuruha Company, Ltd.	3391	P	2	10	96.62	7	12.48
Ad Me Tech	7778	M-D/T/S	3	7	125.00	16	6.78
Techno Medica Co., Ltd.	6678	M-D/T/S	4	12	65.94	12	9.12
Welcia Holdings Co.Limited	3141	P	5	28	23.03	2	30.73

Note: For the sub-industry column above, M-D/T/S = Medical Devices/Technology/Supplies and P = Pharmaceuticals

C-2 Most Profitable

Company	Ticker	Sub-Industry	Overall Rank	Net Income/Total Sales		Net Income/Total Assets		Net Income/Total Equity	
				Rank	Ratio	Rank	Ratio	Rank	Ratio
Santen Pharmaceutical Co., Ltd.	4536	P	1	1	72.38	1	10.26	1	14.40
Asahi Intecc Co., Ltd.	7747	M-D/T/S	2	3	22.85	2	5.03	3	7.95
Kaken Pharmaceutical Co., Ltd.	4521	P	3	4	22.62	3	4.97	5	7.23
Hoya Corporation	7741	M-D/T/S	4	5	20.11	5	3.78	12	4.72
M3 Inc	2413	HS	5	13	17.18	4	4.05	8	5.29

Note: For the sub-industry column above, HS = Health Services, M-D/T/S = Medical Devices/Technology/Supplies, and Pharmaceuticals

C-3 Most Efficient

Company	Ticker	Sub-Industry	Overall Rank	Total Sales/Total Assets		Total Sales/Total Equity	
				Rank	Ratio	Rank	Ratio
Kawanishi Holdings Incorporated	2689	M-D/T/S	1	6	0.75	1	5.19
Medius Holdings Company Limited	3154	M-D/T/S	2	8	0.72	3	4.44
Chuo Bussan Corporation	9852	P	3	4	0.79	8	2.27
Tsuruha Company, Ltd.	3391	P	4	3	0.86	12	1.88
Yamashita Medical Instruments Company Limited	3022	M-D/T/S	5	7	0.74	10	1.98

Note: For the sub-industry column above, M-D/T/S = Medical Devices/Technology/Supplies and P = Pharmaceuticals

C-4 Most Improved

Company	Ticker	Sub - Industry	Sales Growth (Q3-Q2) %	Sales Growth (Q2-Q1) %
Data Horizon Co Ltd	3628	M-D/T/S	55.17	-71.79
Imageone Company Ltd.	2667	M-D/T/S	225.74	-76.35
Jeol Limited	6951	M-D/T/S	55.79	-49.42
Techno Medica Co., Ltd.	6678	M-D/T/S	65.94	-57.55
Trans Genic	2342	B	44.71	-61.54

Note: For the sub-industry column above, B = Biotech and M-D/T/S = Medical Devices/Technology/Supplies

C-5 Multinational Life Science Companies

Company	Ticker	Sub-Industry	Overall Rank	Foreign Sales Current Year		Foreign Sales to Total Sales %		Foreign Sales Growth %	
				Rank	Amount (in USDm)	Rank	Percent	Rank	Ratio
Sysmex Corporation	6869	M-D/T/S	1	11	1208.57	4	78.15	4	17.02
Otsuka Holdings Company Limited	4578	P	2	3	6908.82	11	56.75	7	13.21
Astellas Pharma Inc.	4503	P	3	4	6359.55	7	60.85	15	5.04
Terumo Corporation	4543	M-D/T/S	4	9	2332.30	8	59.55	10	9.99
Canon Electronics Inc.	7739	M-D/T/S	5	1	25164.60	2	80.57	28	14.85

Note: For the sub-industry column above, M-D/T/S = Medical Devices/Technology/Supplies and P = Pharmaceuticals

C-6 Research-Intensive Life Science Companies

Company	Ticker	Sub-Industry	Overall Rank	R&D Exp Current Year		R&D Exp to Total Sales %		R&D Exp Growth %	
				Rank	Amount (in USDm)	Rank	Percent	Rank	Ratio
Ad Me Tech	7778	M-D/T/S	1	9	213.48	3	155.34	1	103.59
Kissei Pharmaceutical Co., Ltd.	4547	P	2	13	121.41	8	20.66	13	9.64
Daiichi Sankyo Company Limited	4568	P	3	3	1597.78	7	20.74	38	-9.76
Astellas Pharma Inc.	4503	P	4	2	1731.26	13	16.56	35	-7.73
Cyberdyne Inc	7779	M-D/T/S	5	48	8.24	2	155.76	10	17.40

Note: For the sub-industry column above, M-D/T/S = Medical Devices/Technology/Supplies and P = Pharmaceuticals

Published by: FinGlobe Inc., **Address:** 5 Independence Way, Suite 300 Princeton, NJ 08540 USA

Phone: 1-609 514 5140 **Fax:** 1-609 514 5104

www: www.finglobedirect.com **Email:** info@finglobedirect.com

To subscribe, please visit <http://finglobedirect.com/index.php/japan-life-sciences-business-daily>

For other publications on Japan Life Sciences Sector, please visit:

<http://finglobedirect.com/index.php/japan-life-sciences>

For our publications on global life sciences sectors, please visit finglobedirect.com.

Please follow us on:



For Japan Life Sciences companies and international companies with activities in Japan's Life Sciences sector, please send news and financial reports to: info@finglobedirect.com Thank you.

Disclaimer: *Japan Life Sciences Daily is based on public domain information believed to be reliable, but no warranties are provided.*

Copyright © 2016 FinGlobe, Inc. USA